SCHEMBL4834459

SCHEMBL4834459

CCN(CC)C(=O)Cc1ccc(NC(=O)/C=C/c2cnn(C)c2-c2ccc(F)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNC P24863 10/20 0.42
CDK8 P49336 10/20 0.42
CDK19 Q9BWU1 2/20 0.42
TDP1 Q9NUW8 2/20 0.39
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
HPSE Q9Y251 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
MMP1 P03956 2/20 0.38
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
GAA P10253 2/20 0.38
EGFR P00533 1/20 0.38
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834478 1.00 CCNC (0.42) CCNCCDK8CDK19TDP1POLB
SCHEMBL4836278 0.91 CCNC (0.43) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4836286 0.91 CCNC (0.43) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4826399 0.88 HPSE (0.49) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4834076 0.88 CCNC (0.45) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4826394 0.88 HPSE (0.49) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4834068 0.88 CCNC (0.45) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4919439 0.87 CCNC (0.45) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4919426 0.87 CCNC (0.45) CCNCCDK8CDK19HPSESMN1; SMN2
SCHEMBL4831457 0.85 CCNC (0.49) CCNCCDK8CDK19TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.